Ipsen S.A. (EPA:IPN)
165.80
+8.60 (5.47%)
Jul 31, 2026, 11:53 AM CET
Ipsen Revenue
Ipsen had revenue of 2.19B EUR in the half year ending June 30, 2026, with 25.03% growth. This brings the company's revenue in the last twelve months to 4.18B, up 11.24% year-over-year. In the year 2025, Ipsen had annual revenue of 3.93B with 9.92% growth.
Revenue (ttm)
4.18B
Revenue Growth
+11.24%
P/S Ratio
3.00
Revenue / Employee
775.30K
Employees
5,535
Market Cap
12.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.93B | 354.70M | 9.92% |
| Dec 31, 2024 | 3.57B | 268.10M | 8.11% |
| Dec 31, 2023 | 3.31B | 149.90M | 4.75% |
| Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
| Dec 31, 2021 | 2.75B | 62.60M | 2.33% |
| Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
| Dec 31, 2019 | 2.69B | 344.30M | 14.66% |
| Dec 31, 2018 | 2.35B | 336.70M | 16.74% |
| Dec 31, 2017 | 2.01B | 340.60M | 20.38% |
| Dec 31, 2016 | 1.67B | 150.90M | 9.93% |
| Dec 31, 2015 | 1.52B | 187.80M | 14.09% |
| Dec 31, 2014 | 1.33B | 50.60M | 3.95% |
| Dec 31, 2013 | 1.28B | 4.40M | 0.34% |
| Dec 31, 2012 | 1.28B | 67.24M | 5.56% |
| Dec 31, 2011 | 1.21B | 39.87M | 3.41% |
| Dec 31, 2010 | 1.17B | 57.92M | 5.21% |
| Dec 31, 2009 | 1.11B | 74.27M | 7.15% |
| Dec 31, 2008 | 1.04B | 44.36M | 4.46% |
| Dec 31, 2007 | 993.76M | 48.50M | 5.13% |
| Dec 31, 2006 | 945.26M | 81.50M | 9.44% |
| Dec 31, 2005 | 863.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 47.35B |
| EssilorLuxottica Société anonyme | 29.29B |
| Eurofins Scientific SE | 7.39B |
| emeis Société anonyme | 5.90B |
| Ramsay Générale de Santé | 5.36B |
| Clariane SE | 5.35B |
| bioMérieux | 3.99B |
| Sartorius Stedim Biotech | 3.01B |
Ipsen News
- 22 hours ago - Ipsen Earnings Call Transcript: Q2 2026 - Transcripts
- 22 hours ago - Ipsen Earnings release: Q2 2026 - Filings
- 22 hours ago - Ipsen Slides: Q2 2026 - Filings
- 22 hours ago - Ipsen Quarterly report: Q2 2026 - Filings
- 7 days ago - Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease - WSJ
- 27 days ago - Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree - WSJ
- 4 weeks ago - Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million - WSJ
- 4 weeks ago - Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio - GlobeNewsWire